Related Experiment Video
Updated: Apr 27, 2026
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
[Advances of immunotherapy in small cell lung cancer]
Jingjing Liu1, Shuang Zhang1, Hui Li2
1Department of Thoracic Oncology, Jilin Provincial Cancer Hospital, Changchun 130012, China.
Abstract:
Small cell lung cancer (SCLC) is complex heterogeneous due to unclear biological characteristics in terms of cell origin, pathogenesis and driver genes etc. Diagnosis and treatment of SCLC has been slowly improved and few breakthroughs have been discovered up to now. Therefore new strategies are urgently needed to improve the efficacy of SCLC treatment. Tumor immunotherapy has potential to restore and trigger the immune system to recognize and eliminate tumor cells, notably it has only minimal adverse impact on normal tissue. Cancer vaccine, adoptive immunotherapy, cytokines and checkpoint inhibitors have now been launched for clinical treatment of SCLC. Ipilimumab is the most promising medicine of immunotherapy. Immunotherapy is expected to bring new vision to the treatment of SCLC. And further researches are needed on such problems affecting efficacy of immunotherapy as the heterogeneity of SCLC, the uncertainty of target for immunotherapy, the immune tolerance, etc.
Insights
Small cell lung cancer (SCLC) remains challenging due to its complexity. Tumor immunotherapy offers a promising new strategy to improve SCLC treatment efficacy with minimal side effects.
Area of Science:
- Oncology
- Immunology
Context:
- Small cell lung cancer (SCLC) presents significant challenges due to its complex and heterogeneous nature, including unclear biological characteristics, cell origin, pathogenesis, and driver genes.
- Current diagnostic and therapeutic approaches for SCLC have seen limited breakthroughs, necessitating the urgent development of novel treatment strategies.
Purpose:
- To explore the potential of tumor immunotherapy as a new strategy to improve the efficacy of small cell lung cancer treatment.
- To review the current landscape of immunotherapeutic agents and their application in SCLC clinical treatment.
Summary:
- Tumor immunotherapy can restore and activate the immune system to target cancer cells, offering a treatment with minimal adverse effects on normal tissues.
- Several immunotherapies, including cancer vaccines, adoptive immunotherapy, cytokines, and checkpoint inhibitors, are now available for SCLC.
- Ipilimumab is highlighted as a particularly promising immunotherapy for SCLC.
Impact:
- Immunotherapy holds the potential to revolutionize SCLC treatment by providing a new therapeutic vision.
- Further research is crucial to address challenges affecting immunotherapy efficacy, such as SCLC heterogeneity, uncertain immunotherapy targets, and immune tolerance.
More Related Videos
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
07:55Flow Cytometry-Based Isolation and Therapeutic Evaluation of Tumor-Infiltrating Lymphocytes in a Mouse Model of Pancreatic Cancer
Published on: January 17, 2025
Related Concept Videos
01:27Tumor Immunotherapy
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
01:30Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...